Bridge's ulcerative colitis candidate headed for Phase II

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said single and multiple ascending doses of oral ulcerative colitis candidate BBT-401 were well tolerated with minimal systemic exposure observed in a Phase I trial in 80 healthy volunteers. The most common adverse events reported in the double-blind, placebo-controlled, U.S. trial were mild diarrhea and headache.

Bridge plans to start a U.S. Phase II trial next month to evaluate BBT-401 in patients with ulcerative colitis...